Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

While it wasn’t found to be superior to that standard therapy for acute pain in both trials, Vertex’s drug offers the possibility to “fill the gap between medicines with good tolerability ...

So, when comparing Netflix Standard vs Premium, which is right for you? Below, we break down the pros and cons of the two pricier options. If you’re ready to sign up, you can do so by hitting ...

Stock markets at close: Nifty Smallcap 100 index enters bear phase; tanks 22% from peak ...

Sends grave threats, sedition raps for review to DOJ The National Bureau of Investigation’s (NBI) ...

Indian biosimilar exports, presently valued at $0.8 billion, are expected to grow fivefold to $4.2 billion by 2030 and reach $30-35 billion by 2047 ...